Investigation of Potential Action on Behalf of Eidos Therapeutics, Inc. (Nasdaq: EIDX) Shareholders
Eidos Therapeutics, Inc. (“Eidos”), a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin or amyloidosis. Kessler Topaz Meltzer & Check, LLP is investigating potential breaches of fiduciary duties and other violations of law by Eidos’s directors and officers relating to the sale of Eidos to BridgeBio Pharma, Inc. (“BridgeBio”), which owns and controls over 63% of Eidos. In connection with the transaction, Eidos’s minority shareholders are expected to receive either 1.85 shares of BridgeBio common stock or $73.26 per share in cash in exchange for each share of Eidos that they own. If you currently own shares of Eidos Therapeutics, Inc. (EIDX), and would like to learn more about our investigation, please fill out our online form or contact us today toll free at 1-844-887-9500 or info@ktmc.com.